1nhaler, a Scotland-based drug delivery device developer, has secured an additional £1.5 million in seed funding to drive development of its novel pop-up cardboard dry powder inhaler (DPI).

The funding round was led by Archangels with support from Scottish Enterprise and BBB Investments. It follows an initial raise of £2 million in 2023 in a funding round also led by Archangels.

The investment will enable 1nhaler to advance its innovative platform technology towards a first Marketing Authorisation Application (MAA) targeted for late 2027. This includes the manufacture of clinical material for regulatory studies and the design of large-scale commercial manufacturing processes.